Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Vroege behandeling van milde tot matige COVID-19 met sotrovimab reduceert risico op progressie
apr 2022 | Pneumonie, Virale infecties